Endocrinology

A Review of the Most-Read Biosimilar Stories in 2020: Part 1

December 24, 2020

Tony Hagen

Article

The top stories in biosimilars for 2020 encompassed biosimilar approvals and launches, the coronavirus disease 2019 pandemic, and the FDA's challenge to stay on top of the rapidly changing health care landscape.

Biocon/Mylan Receive CHMP Nod for Insulin Aspart Biosimilar in European Union

December 14, 2020

Tony Hagen

Article

The positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is expected to be followed by a European Commission final decision early in 2021.

Newly Created Viatris Joins the Biosimilars Forum

November 30, 2020

Tony Hagen

Article

The merger of Pfizer's Upjohn division and Mylan has created a biosimilars powerhouse with global reach.

IGBA Launches Global Biosimilars Week

November 16, 2020

Tony Hagen

Article

The International Generic and Biosimilar Medicines Association (IGBA) hopes to build momentum for the use of biosimilars.

Study: Specialty Drug Spending Net of Rebates Soars for Private Insurance, Medicare Part D

November 2, 2020

Deana Ferreri, PhD

Article

This study of specialty drug spending looks beyond rebates to evaluate growth in spending from 2010 to 2017.

Ten Reasons Why Biosimilar Candidates Should Not Be Tested for Clinical Efficacy

October 31, 2020

Sarfaraz K. Niazi, PhD

Article

The FDA may require comparative clinical efficacy for biosimilar approval, but on top of all the other required and available evidence, these trials add little value, Sarfaraz K. Niazi, PhD, states.

Europeans Devise Checklist for Promoting Biosimilar Use

October 24, 2020

Deana Ferreri, PhD

Article

European investigators have derived a set of core principals for developing higher utilization of biosimilars.

Biocon Reports Biosimilars Revenue Growth

October 23, 2020

Tony Hagen

Article

Biocon had a busy quarter, which included the launch of a long-acting insulin glargine product (Semglee) in partnership with Mylan.

Report: Specialty Drug Assessment Highlights Biosimilar Progress

October 12, 2020

Skylar Jeremias

Article

Sometimes the reference product exhibits pricing resistance against the competitive effect of biosimilars, according to a Pharmaceutical Strategies Group report.

IQVIA: Biosimilars Could Save $100 Billion Over Next 5 Years

October 6, 2020

Skylar Jeremias

Article

A report from the IQVIA Institute for Human Data Science states that assessments of the health of the US biosimilar market are too conservative.

x